Efficacy of Convalescent Plasma Therapy in COVID-19 : A Systematic Review

A type of new-coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) was isolated. The first death caused by this virus occurred on January 9, 2020, in Wuhan and since then >600 million cases and more than six million deaths have occurred worldwide. This disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as the 2019 novel coronavirus (2019-nCoV). The disease is mainly spread between people through respiratory droplets that come from coughing and sneezing.There is currently no treatment that has been shown to be both safe and effective for patients who are suffering from life-threatening complications due to severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2). Convalescent plasma has showed promise as a treatment for adults infected with SARS-CoV 2, but it is not without its downsides. Convalescent immune plasma is plasma that has been obtained from a person who has recovered from an infection and developed antibodies after the infection has been cleared up. The maximum plasma dose that should be administered during convalescence is 5 mL/KgBW. It is advised that patients who are severely ill or in critical condition receive this plasma, but other sites also encourage using it for preventative purposes.